Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7470276 | 1.00 | SIGMAR1 (0.52) | SIGMAR1GRIN2BGRM2KDM4EALDH1A1 | |
| SCHEMBL7528602 | 0.95 | SIGMAR1 (0.53) | SIGMAR1GRM2 | |
| SCHEMBL7488795 | 0.91 | SIGMAR1 (0.50) | SIGMAR1GRM2 | |
| SCHEMBL9676204 | 0.89 | GRM2 (0.57) | SIGMAR1GRM2KDM4EALDH1A1MAPT | |
| SCHEMBL9677541 | 0.89 | GRM2 (0.57) | SIGMAR1GRIN2BGRM2 | |
| Hydrochloric Acid SCHEMBL9679291 | 0.88 | GRM2 (0.56) | SIGMAR1GRM2KDM4EALDH1A1MAPT | |
| SCHEMBL7473692 | 0.87 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL7484050 | 0.86 | CCR3 (0.49) | SIGMAR1 | |
| SCHEMBL7470797 | 0.85 | SIGMAR1 (0.50) | SIGMAR1GRM2ALDH1A1 | |
| SCHEMBL9678366 | 0.81 | GRM2 (0.67) | SIGMAR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061912-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-05-23 | — | — | US | claimed |
| EP-1015447-B1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2002-04-10 | — | — | EP | claimed |
| EP-1015447-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GmbH (DE) | 2000-07-05 | — | — | EP | claimed |
| WO-1999012924-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 1999-03-18 | — | — | WO | claimed |
| CN-1146563-C | Piperidinylmethyloxazolidinone derivative | Ĭ��ר���ɷ�����˾ | 2004-04-21 | — | — | CN | disclosed |
| US-6413989-B1 | 5-(4-(4-FLUOROBENZYL)PIPERIDIN-1-YLMETHYL)-3-(4-HYDROXYPHENYL) OXAZOLIDIN-2-ONE NEUROLEPTIC AGENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6413989-B1 | 5-(4-(4-FLUOROBENZYL)PIPERIDIN-1-YLMETHYL)-3-(4-HYDROXYPHENYL) OXAZOLIDIN-2-ONE NEUROLEPTIC AGENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-20020061912-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-05-23 | — | — | US | disclosed |
| US-20020061912-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-05-23 | — | — | US | disclosed |
| EP-1015447-B1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2002-04-10 | — | — | EP | disclosed |
| EP-1015447-B1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2002-04-10 | — | — | EP | disclosed |
| CN-1269799-A | Piperidinylmethyl oxazolidinone derivatives | MERCK PATENT GMBH (DE) | 2000-10-11 | — | — | CN | disclosed |
| EP-1015447-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GmbH (DE) | 2000-07-05 | — | — | EP | disclosed |
| EP-1015447-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GmbH (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012924-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999012924-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | MERCK PATENT GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061912-A1 | PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE | GRIN2C, GRIN1, GRIN2D | SIGMAR1 135/4885GRIN2B 10/4885GRM2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.